OncBiomune's ProscaVax phase 2 trial investigators
Post# of 110
(Total Views: 646)
Posted On: 06/22/2017 12:35:45 PM
OncBiomune's ProscaVax phase 2 trial investigators Beth Israel Deaconess Medical Center of Harvard Medical School...
Glenn J. Bubley, MD, Director of Genitourinary Oncology
Dr. Glenn Bubley is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials. He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer. Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.
Rupal Bhatt, MD, PhD, MMS
Dr. Rupal Bhatt is Assistant Professor of Medicine at Harvard Medical School, an attending physician in the GU Oncology Program and researcher Dr. Bhatt currently cares for patients with prostate, bladder and testis cancer and has participated in clinical trials in these fields. Dr. Bhatt focuses her research on Renal Cell Carcinoma and Prostate Cancer with a special interest in the Mechanisms of Resistance to Antiangiogenic Therapy. For this work, she was awarded Young Investigator Awards from AACR and ASCO and was also was awarded the ASCO Career Development Award. Currently Dr. Bhatt is in the second year of her five-year Mentored Clinical Scientist Development Award from the National Cancer Institute designed to train clinicians committed to a career in laboratory or field-based research or to translational research with a laboratory focus.
She completed her medical training and graduate training at Cornell University Medical College and The Rockefeller University, where she received her MD/PhD degrees. She trained at BIDMC as an intern and resident and began her research at BIDMC as well as joining the Hematology and Oncology Fellowship program and was recruited to join the medical staff as an attending physician in 2006. In addition to her clinical work and research Dr. Bhatt received her Masters of Medical Science during her participation in the Clinical Investigator Training Program in 2008.
http://www.bidmc.org/Centers-and-Departments/...-team.aspx
Thank you gmwestrup!!!
David Johnson Einstein, MD
Oncology Boston, MA
Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC
Office Address
800 Washington St
Boston, MA 02111Phone
617) 667-2100
Title Clinical Fellow in Medicine (EXT)
Institution Beth Israel Deaconess Medical Center
Department Medicine
Address Beth Israel Deaconess Medical Center
Department of Medicine - Rabb 430
330 Brookline Ave
Boston MA 02215
Phone 617/667-9278
Fax 617/975-5009
Email
Education & Training
Tufts Medical CenterTufts Medical Center
Residency
Tufts University School of MedicineTufts University School of Medicine
Medical School
Other Training Certifications & Licensure
MA State Medical LicenseMA State Medical License 2011 - 2017
American Board of Internal Medicine
Internal Medicine
Awards, Honors, & Recognition
Merit Award in Palliative Care
Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award
Tufts University School of Medicine, 2014
Notable Teaching Citation
Tufts Medical Center Department of Medicine, 2013
Publications & Presentations
PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
Against "Healthy Paternalism" at the End of Life-Reply.
Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.
Journal Articles
The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Abstracts/Posters
"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
Lectures
"'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016
Press Mentions
Peuxvn4ujpboexs1qudvDigital Journal
June 2017
BATON ROUGE, LA—(June 01, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to announce that the protocol for the Company’s upcoming Phase 2 clinical trial of ProscaVax as a novel therapeutic cancer vaccine for early stage prostate cancer has been submitted to the U.S. Food and Drug Administration (FDA) for review. In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients at disease presentation who, in collaboration with their oncologist, chose to forego standard approved therapies in favor of careful monitoring for disease progression, a process known more commonly as “active surveillance.”
ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA (prostate specific antigen) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
There are currently no FDA-approved treatments for patients in active surveillance. Today’s approved therapies for early-stage prostate cancer include surgery to remove the prostate and some surrounding tissue (radical prostatectomy), radiation and brachytherapy, all of which are well documented to have unpleasant side effects, including impotence and urinary incontinence.
As submitted, the Phase 2 clinical protocol will randomly enroll 120 early stage prostate cancer patients with 40 patients on standard active surveillance and 80 patients receiving ProscaVax. The patients’ PSAs and yearly biopsies will be monitored for disease progression. The follow-up of the patients will be for two years. The investigators are Dr. Rupal Bhatt, Dr. Glenn Bubley and Dr. David Einstein at Beth Israel Deaconess Medical Center of Harvard Medical School. Early clinical research of ProscaVax, including a Phase 1 Clinical Trial that recently completed enrollment in PSA progressing prostate cancer in hormone-naïve and hormone-independent patients, has shown ProscaVax to be well tolerated with a strong safety profile. Data from late-stage patients further shows signs of efficacy with respect to an increased immune response and slowing tumor progression.
http://oncbiomune.com/2017/06/01/protocol-sub...te-cancer/
We should hear something in early July on this imo.
Glenn J. Bubley, MD, Director of Genitourinary Oncology
Dr. Glenn Bubley is a renowned expert in genitourinary (GU) medical oncology with a primary focus on prostate cancer. As director of the multidisciplinary genitourinary cancer program involving medical, surgical and radiation oncologists as well as pathologists and basic scientists, he heads numerous clinical/translational trials. He is Co-Principal Investigator for the prestigious Prostate SPORE (Specialized Programs of Research Excellence) at the Dana Farber/Harvard Cancer Center. The research is a pilot of the development of an anti-prostate cancer agent specifically targeted to prostate cancer cells. He oversees the Hershey Family Prostate Cancer Tissue Bank and Data base at BIDMC, which has more than 1,000 specimens from prostate cancer patients over the past 13 years and directs interventional research for GU oncology as well, overseeing approximately 13 open trials for patients with prostate or bladder cancer. Dr. Bubley has authored numerous scientific, research and translation papers and articles in his area of expertise, prostate cancer. He serves as at BIDMC and is Associate Professor of Medicine at Harvard Medical School.
Rupal Bhatt, MD, PhD, MMS
Dr. Rupal Bhatt is Assistant Professor of Medicine at Harvard Medical School, an attending physician in the GU Oncology Program and researcher Dr. Bhatt currently cares for patients with prostate, bladder and testis cancer and has participated in clinical trials in these fields. Dr. Bhatt focuses her research on Renal Cell Carcinoma and Prostate Cancer with a special interest in the Mechanisms of Resistance to Antiangiogenic Therapy. For this work, she was awarded Young Investigator Awards from AACR and ASCO and was also was awarded the ASCO Career Development Award. Currently Dr. Bhatt is in the second year of her five-year Mentored Clinical Scientist Development Award from the National Cancer Institute designed to train clinicians committed to a career in laboratory or field-based research or to translational research with a laboratory focus.
She completed her medical training and graduate training at Cornell University Medical College and The Rockefeller University, where she received her MD/PhD degrees. She trained at BIDMC as an intern and resident and began her research at BIDMC as well as joining the Hematology and Oncology Fellowship program and was recruited to join the medical staff as an attending physician in 2006. In addition to her clinical work and research Dr. Bhatt received her Masters of Medical Science during her participation in the Clinical Investigator Training Program in 2008.
http://www.bidmc.org/Centers-and-Departments/...-team.aspx
Thank you gmwestrup!!!
David Johnson Einstein, MD
Oncology Boston, MA
Genitourinary Oncology, Hematologic Oncology, Hospice & Palliative Fellow, BIDMC
Office Address
800 Washington St
Boston, MA 02111Phone
617) 667-2100 Title Clinical Fellow in Medicine (EXT)
Institution Beth Israel Deaconess Medical Center
Department Medicine
Address Beth Israel Deaconess Medical Center
Department of Medicine - Rabb 430
330 Brookline Ave
Boston MA 02215
Phone 617/667-9278
Fax 617/975-5009
Education & Training
Tufts Medical CenterTufts Medical Center
Residency
Tufts University School of MedicineTufts University School of Medicine
Medical School
Other Training Certifications & Licensure
MA State Medical LicenseMA State Medical License 2011 - 2017
American Board of Internal Medicine
Internal Medicine
Awards, Honors, & Recognition
Merit Award in Palliative Care
Conquer Cancer Foundation of ASCO, 2014
Excellence in Teaching Award
Tufts University School of Medicine, 2014
Notable Teaching Citation
Tufts Medical Center Department of Medicine, 2013
Publications & Presentations
PubMed Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies.
Einstein, D. J.,DeSanto-Madeya, S.,Gregas, M.,Lynch, J.,McDermott, D. F.,Buss, M. K.; J Oncol Pract. 2017 Jun 01.
Against "Healthy Paternalism" at the End of Life-Reply.
Mathew P, Einstein DJ, Ladin K; JAMA Oncol. 2016-06-01.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life.
Einstein, D. J.,Ladin, K.,Mathew, P.; JAMA Oncol. 2016 Feb 26.
Journal Articles
The ethical imperative of healthy paternalism in advance-directive discussions at the end of life Einstein DJ, Ladin K, and Mathew P, JAMA Oncol, 1/25/2016
Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey Einstein DJ, Einstein KL, and Mathew P, J Palliat Med, 1/1/2015
A problematic palsy: an exercise in clinical reasoning Einstein DJ, Trowbridge RL, and Rencic J, J Gen Int Med, 1/1/2015
Abstracts/Posters
"Expanded Prostate Cancer Index Composite-26 Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life after Treatment for Lo... Einstein DJ, American Urological Association Annual Meeting, San Diego, CA, 1/1/2016
"Dying for advice: code-status discussions between resident physicians patients with advanced cancer-a national survey." Einstein DJ, ASCO Palliative Care in Oncology Symposium, Boston, MA, 1/1/2014
Lectures
"'Who Am I to Say?' The Role of Residents in Advance Care Planning." Boston, MA - 1/1/2016
Press Mentions
Peuxvn4ujpboexs1qudvDigital Journal
June 2017
BATON ROUGE, LA—(June 01, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to announce that the protocol for the Company’s upcoming Phase 2 clinical trial of ProscaVax as a novel therapeutic cancer vaccine for early stage prostate cancer has been submitted to the U.S. Food and Drug Administration (FDA) for review. In the trial, ProscaVax will be evaluated for safety, tolerability and efficacy as a treatment for patients at disease presentation who, in collaboration with their oncologist, chose to forego standard approved therapies in favor of careful monitoring for disease progression, a process known more commonly as “active surveillance.”
ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA (prostate specific antigen) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
There are currently no FDA-approved treatments for patients in active surveillance. Today’s approved therapies for early-stage prostate cancer include surgery to remove the prostate and some surrounding tissue (radical prostatectomy), radiation and brachytherapy, all of which are well documented to have unpleasant side effects, including impotence and urinary incontinence.
As submitted, the Phase 2 clinical protocol will randomly enroll 120 early stage prostate cancer patients with 40 patients on standard active surveillance and 80 patients receiving ProscaVax. The patients’ PSAs and yearly biopsies will be monitored for disease progression. The follow-up of the patients will be for two years. The investigators are Dr. Rupal Bhatt, Dr. Glenn Bubley and Dr. David Einstein at Beth Israel Deaconess Medical Center of Harvard Medical School. Early clinical research of ProscaVax, including a Phase 1 Clinical Trial that recently completed enrollment in PSA progressing prostate cancer in hormone-naïve and hormone-independent patients, has shown ProscaVax to be well tolerated with a strong safety profile. Data from late-stage patients further shows signs of efficacy with respect to an increased immune response and slowing tumor progression.
http://oncbiomune.com/2017/06/01/protocol-sub...te-cancer/
We should hear something in early July on this imo.
(0)
(0)Theratechnologies Inc. (THER) Stock Research Links
Scroll down for more posts ▼